Clinical Trials Browser

Phase 2 × NIH × Atorvastatin × Clear all

NCT04915183 2026-03-09

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT00335504 2017-02-15

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Phase 2 Completed

85 enrolled 10 charts

GastrointestinalOther neoplasm

Colonic Neoplasms, Precancerous Conditions, Rectal Neoplasms